| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Gilead Sciences Inc. | GLPG1972 - (ROCCELLA) | Osteoarthritis | Phase 2b | Trial Completed | Oral | Orthopedic |
| Gilead Sciences Inc. | Filgotinib and GS-9876 | Cutaneous lupus erythematosus (CLE) | Phase 2 | Trial Discontinued | Oral | Immunology |
| Gilead Sciences Inc. | Magrolimab | Colorectal cancer | Phase 2 | Trial Discontinued | Intravenous | Oncology |
| Gilead Sciences Inc. | Magrolimab | Solid tumors | Phase 2 | Trial Discontinued | Intravenous | Oncology |
| Gilead Sciences Inc. | Filgotinib - (OLINGUITO) | Ankylosing spondylitis | Phase 2 | Enrollment Initiation | Oral | Immunology: Anti-TNF |
| Gilead Sciences Inc. | CART-ddBCMA - (iMMagine-1) | Multiple Myeloma | Phase 2 | Data Released | Intravenous | Oncology |
| Gilead Sciences Inc. | Cilofexor (GS-9674) | Primary sclerosing cholangitis (PSC) | Phase 3 | Trial Discontinued | oral | Gastroenterology |
| Gilead Sciences Inc. | MBX-2982 | Type 1 diabetes | Phase 2a | Data Released | oral | Endocrinology |